Skip to content

The Healing Effect of a Herbal Gel Containing Arrabidaea chica in the Treatment of Mouth Wounds in patients with Head and Neck Cancer

Arrabidaea chica for Oral Mucositis in patients with Head and Neck Cancer: a Protocol of a Randomized Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-5x4397
Enrollment
Unknown
Registered
2017-11-14
Start date
2017-08-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mucositis

Interventions

Experimental group A: Seventy individuals enrolled in the arm of Arrabidaea chica will receive tubes of an herbal gel containing 2.5% of the active standardized arrabidaea chica extract and will be in
Drug
Device
E02.594

Sponsors

Hospital de Clínicas da Universidade Estadual de Campinas
Lead Sponsor
Fundação de Amparo à Pesquisa do estado de São Paulo
Collaborator
Faculdade de Ciências Farmacêuticas da Universidade Estadual de Campinas
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Men and women over 18 years old; squamous cell carcinoma of the head and neck; chemotherapy with cisplatin or carboplatin associated with radiotherapy; signs/symptoms of oral mucositis.

Exclusion criteria

Exclusion criteria: Tumor of a histological type other than carcinoma; nasopharyngeal tumor; ulcerative lesions; infections in the oral cavity before.

Design outcomes

Primary

MeasureTime frame
Primary outcome will be mean duration of mucositis in days, measured by the mean and standard deviation of each group and association will be assessed by mean difference and 95% confidence interval. Mucositis will be measured by the Radiation Therapy Oncology Group scale to classify the effects of radiotherapy and the World Health Organization mucositis assessment scale. It is expected that there will be a reduction in the mean duration of oral mucositis in days. Oral mucositis from grade 2 or worse , measured through the mucositis scale of the World Health Organization, made pre intervention.

Secondary

MeasureTime frame
Secondary outcome will include pain assessment, using a visual analogue scale (VAS) from 0 (no pain) to 10 (unbearable pain) and quality adjusted life years (QALY) by European Quality of Life 5-Dimensions (EQ-5D). Furthermore, a measurement of the diameter, in millimeters, of the oral lesion using a millimeter periodontal probe (Williams’s model) will be taken. Each patient will have their mouth photographed at enrolment and during intervention for documentation of the degree and extention of oral mucositis. Photographs will be read in ImageJ software. It is expected that there will be a reduction in the mean duration of oral mucositis in days. Pain assessment using a visual analogue scale (VAS) from 0 (no pain) to 10 (unbearable pain) and quality adjusted life years (QALY) by the European 5-Dimensional Quality of Life (EQ-5D); measurement of the diameter, in millimeters, of the oral lesion using a millimetric periodontal probe (Williams model), done before intervention. Photographic image of the mouth, pre and post intervention.

Countries

Brazil

Contacts

Public ContactMary Ann Foglio

Faculdade de Ciências Farmacêuticas-Unicamp

maryann.foglio@fcf.unicamp.br+55193521-7067

Outcome results

None listed

Source: REBEC (via WHO ICTRP)